Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands

Abstract

The objective of this study was to investigate whether the presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid (CSF) influences the response to treatment with beta-interferon in relapsing—remitting multiple sclerosis (RRMS) patients. We performed a collaborative prospective study including RRMS patients with brain MRI and LS-OCMB studies performed before starting interferon treatment. The primary endpoint was the risk of having a relapse after treatment initiation. Secondary endpoints included relapse rate, relapse-rate reduction, proportion of relapse-free patients and proportion of patients with sustained disability increase during follow-up. One-hundred and two patients were included. After a mean follow-up of 37.4 months, the risk of suffering a relapse was two-fold higher in patients with LS-OCMB (hazard ratio 2.0, 95% confidence interval 1.1—3.8). LS-OCMB+ patients showed lower reduction in relapse rate (51.8% versus 80.8%; p < 0.0001), higher relapse rate in the first year (0.8 versus 0.2; p = 0.001), lower proportion of relapse-free patients (25% versus 61.3%; p = 0.003), and higher proportion of patients with sustained 1.0 increase in the Expanded Disability Status Score (45% versus 12.9%; p = 0.0003). In conclusion, LS-OCMB can have an influence on the response to interferon treatment in RRMS patients. They could be used as a biological marker to predict high inflammatory activity after treatment.

Keywords

beta-interferon cerebrospinal fluid multiple sclerosis oligoclonal bands outcome measurement

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM , et al. Intramuscular interferon beta-1a for disease progression in relapsing Multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.

Cohen BA , Khan O. , Jeffery DR , Bashir K. , Rizvi SA , Fox EJ , et al. Identifying and treating patients with suboptimal responses . Neurology 2004; 63: S33-S40.

Liu C. and Blumhardt LD

Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better?

Mult Scler 1999 ; 5: 22-28.

O’Rourke K. , Walsh C. , Antonelli G. and Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342.

Bosca I. , Coret F. , Valero C. , Pascual AM , Magraner MJ , Landete L. , et al. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta interferon. Mult Scler 2008; 14: 636-639.

Villar LM , Masjuan J. , González-Porqué P. , Plaza J. , Sádaba MC , Roldán E. , et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 556-559.

Villar LM , Masjuan J. , González-Porqué P. , Plaza J. , Sádaba MC , Roldán E. , et al. Intrathecal IgM synthesis is a prognostic factor in multiple Sclerosis. Ann Neurol 2003 ; 53: 222-226.

10.

Villar LM , Masjuan J. , González-Porqué P. , Plaza J. , Sádaba MC , Roldán E. , et al. Intrathecal IgM synthesis in neurological diseases. Relationship with disability in MS. Neurology 2002; 58: 824-826.

11.

Villar LM , Sádaba MC , Roldán E. , Masjuan J. , González-Porqué P. , Villarrubia N. , et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.

12.

Thangarajh M. , Gomez-Rial J. , Hedström AK , Hillert J. , Alvarez-Cermeño JC , Masterman T. , et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis . Mult Scler 2008; 14: 1208-1213.

13.

García-Barragán N. , Villar LM , Espiño M. , Sádaba MC , González-Porqué P. and Alvarez-Cermeño JC Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol 2009; 16: 380-385.

14.

Polman CH , Reingold SC , Edan G. , Filippi M. , Hartung HP , Kappos L. , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Ann Neurol 2005; 58: 840-846.

15.

Poser CM , Paty DW , Scheinberg L. , McDonald WI , Davis FA , Ebers GC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.

16.

Villar LM , González-Porqué P. , Masjuán J. , Alvarez-Cermeño JC , Bootello A. and Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands . J Immunol Methods 2001; 258: 151-155.

17.

Sádaba MC , González-Porqué P. , Masjuan J. , ÁlvarezCermeño JC , Bootello A. and Villar LM An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004; 284: 141-145.

18.

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ , et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.

19.

Comi G. , Filippi M. , Barkhof F. , Durelli L. , Edan G. , Fernández O. , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.

20.

Kappos L. , Polman CH , Freedman MS , Edan G. , Hartung HP , Miller DH , et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.